| 25.07 08:07 | dpa-AFX: *ASTRAZENECA EXPECTS FY TOTAL REVENUE AND CORE EPS TO GROW BY A MID TEENS PERCENTAGE AT CER |
| 25.07 08:07 | dpa-AFX: *ASTRAZENECA HY CORE EPS INCREASE 5% TO $4.03; INCREASES INTERIM DIVIDEND BY 7 CENTS TO $1.00 |
| 25.07 08:06 | dpa-AFX: *ASTRAZENECA HY TOTAL REVENUES $25.62 BLN VS $22.30 BLN PRIOR YEAR |
| 25.07 08:05 | dpa-AFX: *ASTRAZENECA HY ATTRIBUTABLE PROFIT $4.11 BLN VS $3.62 BLN PRIOR YEAR |
| 25.07 08:04 | dpa-AFX: *ASTRAZENECA HY EPS $2.63 VS $2.32 PRIOR YEAR |
| 25.07 08:03 | dpa-AFX: *ASTRAZENECA H1 REPORTED EPS $2.65; CORE EPS $4.03 |
| 23.07 14:15 | dpa-AFX: AstraZeneca Says Voydeya Approved In Canada As Add-on To Ravulizumab Or Eculizumab For PNH |
| 23.07 13:13 | dpa-AFX: *ASTRAZENECA: VOYDEYA APPROVED IN CANADA AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB FOR ADULTS WITH PNH |
| 23.07 12:03 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 23.07 12:03 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 23.07 11:47 | dpa-AFX: VERMISCHTES/ROUNDUP: RSV-Schutz für Babys auf Kassenkosten in Sicht |
| 17.07 16:52 | dpa-AFX: ROUNDUP 2/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 16:52 | ROUNDUP 2/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 16:47 | dpa-AFX: ROUNDUP 2/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 11:18 | dpa-AFX: ROUNDUP/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 11:18 | ROUNDUP/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 17.07 11:13 | dpa-AFX: ROUNDUP/Gericht zu Covid-Impfstoff: EU-Kommission gab zu wenig Infos |
| 15.07 08:05 | dpa-AFX: *ASTRAZENECA COMPLETES ACQUISITION OF AMOLYT PHARMA |
| 15.07 08:02 | dpa-AFX: *ASTRAZENECA COMPLETES ACQUISITION OF AMOLYT PHARMA |
| 10.07 12:13 | dpa-AFX: ANALYSE-FLASH: Deutsche Bank Research belässt Astrazeneca auf 'Hold' |
|
|
